The Predictive Value of Longitudinal Monitoring of Mutated EGFR in Plasma of Advanced NSCLC Patients on First-Line EGFR-TKIs

被引：0
|
作者：
Szpechcinski, A. [1 ]
Bryl, M. [2 ]
Wojda, E. [1 ]
Czyzewicz, G. [3 ]
Swiniuch, D. [4 ]
Szwiec, M. [5 ]
Ramlau, R. [4 ]
Sliwinski, P. [1 ]
Barinow-Wojewodzki, A. [2 ]
Chorostowska-Wynimko, J. [1 ]
机构：
[1] Inst TB & Lung Dis, Warsaw, Poland
[2] EJ Zeyland Wielkopolska Ctr Pulmonol & Thorac Sur, Poznan, Poland
[3] John Paul II Specialist Hosp, Krakow, Poland
[4] Med Univ Poznan, Poznan, Poland
[5] Univ Hosp Zielona Gora, Zielona Gora, Poland
来源：
JOURNAL OF THORACIC ONCOLOGY | 2022年 / 17卷 / 09期
关键词：
non-small cell lung cancer; EGFR mutations; liquid biopsy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
EP08.02-07
引用
收藏
页码：S434 / S435
页数：2
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations
    Marscha S. Holleman
    Maiwenn J. Al
    Remziye Zaim
    Harry J. M. Groen
    Carin A. Uyl-de Groot
    The European Journal of Health Economics, 2020, 21 : 153 - 164
  • [32] Impact of detecting plasma EGFR mutations with ultrasensitive liquid biopsy in outcomes of NSCLC patients treated with first- or second-generation EGFR-TKIs
    Arrieta, Oscar
    Hernandez-Martinez, Juan-Manuel
    Montes-Servin, Edgar
    Heredia, David
    Cardona, Andres F.
    Molina-Romero, Camilo
    Lara-Mejia, Luis
    Diaz-Garcia, Diego
    Bahena-Gonzalez, Antonio
    Mendoza-Oliva, Dolores L.
    CANCER BIOMARKERS, 2021, 32 (02) : 123 - 135
  • [33] Phase I Study Evaluating the Combination of Afatinib with Carboplatin and Pemetrexed After First-line EGFR-TKIs
    Watanabe, Satoshi
    Yamaguchi, Ou
    Masumoto, Ai
    Maeno, Yuri
    Kawashima, Yosuke
    Ishimoto, Osamu
    Sugawara, Shunichi
    Yoshizawa, Hirohisa
    Kikuchi, Toshiaki
    Nukiwa, Toshihiro
    Kobayashi, Kunihiko
    ANTICANCER RESEARCH, 2018, 38 (08) : 4699 - 4704
  • [34] Low Prognostic Nutritional Index Correlates with Worse Survival in Patients with Advanced NSCLC following EGFR-TKIs
    Sheng, Jin
    Zhang, Li
    Yang, Yunpeng
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S230 - S230
  • [35] Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
    Nardo, Giorgia
    Carlet, Jessica
    Marra, Ludovica
    Bonanno, Laura
    Boscolo, Alice
    Dal Maso, Alessandro
    Boscolo Bragadin, Andrea
    Indraccolo, Stefano
    Zulato, Elisabetta
    FRONTIERS IN ONCOLOGY, 2021, 10
  • [36] Monitoring cfDNA in Plasma and in Other Liquid Biopsies of Advanced EGFR Mutated NSCLC Patients: A Pilot Study and a Review of the Literature
    Verze, Michela
    Minari, Roberta
    Gnetti, Letizia
    Bordi, Paola
    Leonetti, Alessandro
    Cosenza, Agnese
    Ferri, Leonarda
    Majori, Maria
    De Filippo, Massimo
    Buti, Sebastiano
    Gasparro, Donatello
    Nizzoli, Rita
    Azzoni, Cinzia
    Bottarelli, Lorena
    Squadrilli, Anna
    Mozzoni, Paola
    Tiseo, Marcello
    CANCERS, 2021, 13 (21)
  • [37] Characterization of PD-L1 Expression and Its Predictive and Prognostic Significance in EGFR-Mutant NSCLC Patients Treated with EGFR-TKIs
    Jiang, T.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2209 - S2209
  • [38] Circulating tumour DNA: A new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs
    Diao, Zhenli
    Han, Yanxi
    Zhang, Rui
    Li, Jinming
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (02):
  • [39] Comparative Efficacy and Safety of TKIs Alone or in Combination With Antiangiogenic Agents in Advanced EGFR-Mutated NSCLC as the First-Line Treatment: A Systematic Review and Meta-Analysis
    Zhang, Shuang
    Li, Shuang
    Liu, Jingjing
    Yang, Changliang
    Zhang, Liang
    Bao, Hao
    Cheng, Ying
    CLINICAL LUNG CANCER, 2022, 23 (02) : 159 - 169
  • [40] PREDICTION OF PROGNOSIS OF ADVANCED NSCLC PATIENTS AFTER EGFR-TKIS THERAPY BY THE LEVEL OF IL-6 IN PLEURA
    Tian, Wen
    Sun, Si
    Wu, Yu
    ACTA MEDICA MEDITERRANEA, 2022, 38 (05): : 3589 - 3593
12345